Reset filter
Keywords
Pathology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

159 Search results.
Relevance Rating New first Old first

UKHD - Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Verlaufsangaben

- 3/9/22 - 10 forms, 3 itemgroups, 38 items, 1 language
Itemgroups: Verlaufsangaben, Präoperative Vorbereitung - Checkliste, OP und Verlauf
Routinedokumentation der Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Multimodale Brustdiagnostik. Sektionsleiter Senologie: Prof. Dr. med. Jörg Heil, MHBA

Empfehlung des postoperativen Tumorboards

1 itemgroup 26 items

Poststationäre Ergänzungen

1 itemgroup 2 items

Pathologie

3 itemgroups 121 items

Procedere

1 itemgroup 27 items

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 3 itemgroups, 22 items, 1 language
Itemgroups: Admininstrative data, Bone marrow biopsy, Biopsy Tumor
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Central Pathology Assessment and Description

- 9/20/21 - 1 form, 7 itemgroups, 21 items, 1 language
Itemgroups: Biopsy, Biopsy , Lymphoma, Non-Hodgkin | Classification, Pathologist evaluation | Central, Basis of Assessment, Pathologist evaluation | Central | Description, Administrative
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy NCT00989664 - Central Pathology Assessment

- 9/20/21 - 1 form, 3 itemgroups, 18 items, 1 language
Itemgroups: Central Pathology Assessment, Pathology Assessment Description, Administration
https://clinicaltrials.gov/show/NCT00989664 Central Pathology Assessment Study ID: 104504 Clinical Study ID: BEX104504 Study Title: Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00989664 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

HIS pathology report - organ prostate cancer - HIS

- 9/20/21 - 1 form, 10 itemgroups, 60 items, 2 languages
Itemgroups: Admininstrative Daten, Tumordiagnose, Tumorhistologie, Histologie, Gleason-Score, verschiedene Kriterien, Pathologischer TNM, Gewebeprobe Anzahl, Größe der Tumorprobe, Lokalisation von Fernmetastasen
HIS form from Soarian. Urologie Erlangen" with friendly permission of the urology Erlangen (Prof. Wullich) and the medical informatics department Erlangen (PD Dr. Bürkle)

Local Pathology Results GSK study Prostatic neoplasms NCT00883909

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Administrative data, Pathology Results
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Leukemia Daunorubicin Cytarabine Oblimersen NCT00085124 CALGB - Cytogenetics

- 9/20/21 - 1 form, 1 itemgroup, 25 items, 1 language
Itemgroup: Cytogenetics
CALGB: CYTOGENETICS REFERRAL FORM NCT00085124 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229EF62-6ADF-5120-E034-0003BA12F5E7

CALGB_40302_TISS_TRCK_FRM NCT00390455

- 9/20/21 - 1 form, 3 itemgroups, 24 items, 1 language
Itemgroups: Header, Patient demographics, TISSUE TRACKING
CALGB: 40302 TISSUE TRACKING FORM NCT00390455 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F5AC8F60-F3F9-0DB4-E034-0003BA3F9857

Pathology - Leukemia Pathology Form - Cytogenetics - 2019350v3.0 - Leukemia Pathology Form - Cytogenetics

- 9/20/21 - 1 form, 3 itemgroups, 47 items, 1 language
Itemgroups: CRF Header, Pathology: Form Administration, Pathology: Cytogenetic Assessment
Leukemia Pathology Form - Cytogenetics Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B4D83AE-8665-6A50-E044-0003BA3F9857

Brain and Central Nervous System Tumors NCT00887146 Pathology - North Central Cancer Treatment Group N0577 Pathology Submission Form - 2745984v1.0 - North Central Cancer Treatment Group N0577 Pathology Submission Form

- 9/20/21 - 1 form, 4 itemgroups, 20 items, 1 language
Itemgroups: Header, Header, Institution Contact Information (Please Print), Footer Module
North Central Cancer Treatment Group N0577 Pathology Submission Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C08FC47-BFC6-632C-E044-0003BA3F9857

CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534

- 9/20/21 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Header, Patient demographics, SPECIMEN SUBMISSION
CALGB: 90104 SPECIMEN SUBMISSION FORM NCT00014534 Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E5F4A97F-274E-398C-E034-0003BA3F9857

Pathology - Lung Cancer - North Central Cancer Treatment Group N0723 Pathology Reporting Form - 2731651v1.0 - Lung Cancer - North Central Cancer Treatment Group N0723 Pathology Reporting Form

- 9/20/21 - 1 form, 9 itemgroups, 59 items, 1 language
Itemgroups: Header Module, Pathology Reporting, Lung Surgery, Disease Characteristics, Disease Characteristics2, Comments and Pathology Reporting, EGFR FISH Status, EGFR IHC Status, Comments and Pathology Reporting2
North Central Cancer Treatment Group N0723 Pathology Reporting Form; ***This CRF DELETED FROM STUDY, so no response to initial CDE-compliance review.*** Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=46FF63E8-1059-1831-E044-0003BA3F9857

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial